JP7320741B2 - Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 - Google Patents

Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 Download PDF

Info

Publication number
JP7320741B2
JP7320741B2 JP2017553956A JP2017553956A JP7320741B2 JP 7320741 B2 JP7320741 B2 JP 7320741B2 JP 2017553956 A JP2017553956 A JP 2017553956A JP 2017553956 A JP2017553956 A JP 2017553956A JP 7320741 B2 JP7320741 B2 JP 7320741B2
Authority
JP
Japan
Prior art keywords
compound
cancer
salt
crystalline form
sesquimaleate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017553956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511634A5 (https=
JP2018511634A (ja
Inventor
チャン、グオリャン
チョウ、チャンヨウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines Ltd
Original Assignee
BeOne Medicines Ltd
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BeOne Medicines Ltd, Beigene Ltd filed Critical BeOne Medicines Ltd
Publication of JP2018511634A publication Critical patent/JP2018511634A/ja
Publication of JP2018511634A5 publication Critical patent/JP2018511634A5/ja
Priority to JP2021009106A priority Critical patent/JP7383652B2/ja
Application granted granted Critical
Publication of JP7320741B2 publication Critical patent/JP7320741B2/ja
Priority to JP2023190552A priority patent/JP2024012540A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2017553956A 2015-04-15 2016-04-14 Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 Active JP7320741B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021009106A JP7383652B2 (ja) 2015-04-15 2021-01-22 Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
JP2023190552A JP2024012540A (ja) 2015-04-15 2023-11-08 Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/076639 2015-04-15
CN2015076639 2015-04-15
PCT/CN2016/079251 WO2016165626A1 (en) 2015-04-15 2016-04-14 Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021009106A Division JP7383652B2 (ja) 2015-04-15 2021-01-22 Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用

Publications (3)

Publication Number Publication Date
JP2018511634A JP2018511634A (ja) 2018-04-26
JP2018511634A5 JP2018511634A5 (https=) 2019-05-23
JP7320741B2 true JP7320741B2 (ja) 2023-08-04

Family

ID=57125563

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017553956A Active JP7320741B2 (ja) 2015-04-15 2016-04-14 Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
JP2021009106A Active JP7383652B2 (ja) 2015-04-15 2021-01-22 Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
JP2023190552A Withdrawn JP2024012540A (ja) 2015-04-15 2023-11-08 Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021009106A Active JP7383652B2 (ja) 2015-04-15 2021-01-22 Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
JP2023190552A Withdrawn JP2024012540A (ja) 2015-04-15 2023-11-08 Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用

Country Status (15)

Country Link
US (1) US10351559B2 (https=)
EP (2) EP3283486B1 (https=)
JP (3) JP7320741B2 (https=)
KR (2) KR102643609B1 (https=)
CN (2) CN113307805A (https=)
AU (1) AU2016248376B2 (https=)
CA (1) CA2981746C (https=)
EA (1) EA035680B1 (https=)
IL (2) IL287740B2 (https=)
MX (1) MX381053B (https=)
NZ (1) NZ735715A (https=)
SG (1) SG11201707984TA (https=)
TW (4) TWI792406B (https=)
WO (1) WO2016165626A1 (https=)
ZA (1) ZA201706392B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024012540A (ja) * 2015-04-15 2024-01-30 ベイジーン リミテッド Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
US9273046B2 (en) 2011-12-31 2016-03-01 Beigene, Ltd. Fused tricyclic compounds as Raf kinase inhibitors
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
WO2020033344A1 (en) * 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
HUE062000T2 (hu) * 2018-10-31 2023-09-28 Servier Lab BCL-2 inhibitor új sója, vonatkozó kristályforma, ezek elõállítási eljárása és ezeket tartalmazó gyógyszerkészítmények
CN111484488A (zh) * 2019-01-25 2020-08-04 百济神州(北京)生物科技有限公司 一种b-raf激酶二聚体抑制剂的稳定结晶形式a
CN111484489B (zh) * 2019-01-25 2023-05-23 百济神州(北京)生物科技有限公司 无定形的b-raf激酶二聚体抑制剂
EP3937936A4 (en) * 2019-03-15 2022-12-28 Forma Therapeutics, Inc. INHIBITION OF CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB)
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
CN111184693B (zh) * 2019-05-29 2023-07-21 百济神州(苏州)生物科技有限公司 一种raf激酶抑制剂制剂及其制备方法
US20230128315A1 (en) * 2020-04-03 2023-04-27 Beigene, Ltd. Co-administration of mirdametinib and lifirafenib for use in treating cancers
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
WO2023240178A1 (en) * 2022-06-08 2023-12-14 Mapkure, Llc Methods of treating cancer with a b-raf inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015506353A (ja) 2011-12-31 2015-03-02 ベイジーン リミテッド Ｒａｆキナーゼ阻害剤としての縮合三環式化合物
JP2021073246A (ja) 2015-04-15 2021-05-13 ベイジーン リミテッド Ｂ−ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005316668B2 (en) 2004-12-13 2012-09-06 Millennium Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
CN101365682A (zh) 2005-12-08 2009-02-11 千禧药品公司 具有激酶抑制活性的双环化合物
ATE552245T1 (de) 2006-05-15 2012-04-15 Merck Sharp & Dohme Antidiabetische bicyclische verbindungen
US20100292205A1 (en) 2006-08-23 2010-11-18 Pfizer Inc. Pyrimidone Compounds As GSK-3 Inhibitors
EP2061761A1 (en) 2006-09-07 2009-05-27 Millennium Pharmaceuticals, Inc. Phenethylamide derivatives with kinase inhibitory activity
EA016329B1 (ru) 2007-05-04 2012-04-30 Айрм Ллк СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
US20100197924A1 (en) 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds
CN103476770B (zh) * 2010-11-25 2017-02-15 拉蒂欧制药有限责任公司 阿法替尼盐和多晶型物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015506353A (ja) 2011-12-31 2015-03-02 ベイジーン リミテッド Ｒａｆキナーゼ阻害剤としての縮合三環式化合物
JP2021073246A (ja) 2015-04-15 2021-05-13 ベイジーン リミテッド Ｂ−ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｃ．Ｇ．ＷＥＲＭＵＴＨ編，「最新 創薬化学 下巻」，株式会社 テクノミック，１９９９年，ｐｐ．３４７－３６５
平山令明，有機化合物結晶作製ハンドブック －原理とノウハウ－，２００８年 ７月２５日，ｐ．１７－２３，３７－４０，４５－５１，５７－６５
真野高司，創薬の探索段階における薬剤学的研究の意義と実践，日本薬理学雑誌，２００９年 ３月 １日，第１３３巻，第３号，第１４９－１５３頁

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024012540A (ja) * 2015-04-15 2024-01-30 ベイジーン リミテッド Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用

Also Published As

Publication number Publication date
MX381053B (es) 2025-03-12
TW202330526A (zh) 2023-08-01
US10351559B2 (en) 2019-07-16
EP3283486B1 (en) 2022-07-27
TW202138370A (zh) 2021-10-16
TW202434587A (zh) 2024-09-01
KR20240049684A (ko) 2024-04-16
JP2021073246A (ja) 2021-05-13
EP3283486A1 (en) 2018-02-21
KR20170139073A (ko) 2017-12-18
NZ735715A (en) 2022-09-30
AU2016248376B2 (en) 2020-10-08
IL255555B (en) 2021-12-01
CA2981746A1 (en) 2016-10-20
CN113307805A (zh) 2021-08-27
TWI876835B (zh) 2025-03-11
AU2016248376A1 (en) 2017-10-12
JP2018511634A (ja) 2018-04-26
EP4119559A1 (en) 2023-01-18
ZA201706392B (en) 2019-05-29
SG11201707984TA (en) 2017-11-29
EA035680B1 (ru) 2020-07-24
JP7383652B2 (ja) 2023-11-20
IL255555A (en) 2018-01-31
TWI736531B (zh) 2021-08-21
CA2981746C (en) 2023-08-01
IL287740A (en) 2021-12-01
JP2024012540A (ja) 2024-01-30
CN107531682A (zh) 2018-01-02
CN107531682B (zh) 2021-05-04
BR112017020945A2 (pt) 2018-07-10
EA201792254A1 (ru) 2018-02-28
IL287740B2 (en) 2025-11-01
IL287740B1 (en) 2025-07-01
US20180127412A1 (en) 2018-05-10
KR102643609B1 (ko) 2024-03-05
TW201702241A (zh) 2017-01-16
TWI792406B (zh) 2023-02-11
EP3283486A4 (en) 2018-08-22
TWI832668B (zh) 2024-02-11
WO2016165626A1 (en) 2016-10-20
MX2017013219A (es) 2018-02-15

Similar Documents

Publication Publication Date Title
JP7383652B2 (ja) Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
US12410189B2 (en) Polymorphs and solid forms of (S)-2-2((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9- yl)amino)propanamide, and methods of production
CN113788824A (zh) 吡啶化合物
TWI786303B (zh) 抑制ｃｄｋ4/6活性化合物的晶型及其應用
JP2020526593A (ja) Ｎ−フェニル−２−アミノピリミジン類化合物の結晶形、塩形態及びその製造方法
HK40084617A (en) Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
HK40049820A (en) Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
TW202542122A (zh) 包含（５ｒ，６ｓ）—１０，１１—二氟—１２—（（２—氟—４—碘苯基）—５，６—二羥基—４，５，６，７—四氫—１１１—螺［苯并［ｂ］［１，５，４］氧雜噻西啶—３，１＇—環丙烷］２，２—二氧化物之固體形式以及包含其之組合物及使用其之方法
US20210340142A1 (en) Salt form and crystal form of novel azatricyclic compound and use thereof
WO2025237418A1 (zh) 一种cdk2抑制剂的盐、晶型及其制备方法和应用
BR112017020945B1 (pt) Sais cristalinos de sesqui-maleato de um inibidor de quinase b-raf, método e processo de preparação e usos dos mesmos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180215

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200424

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200923

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210122

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210122

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210202

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210209

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210319

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210323

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220517

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220628

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221226

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230712

R150 Certificate of patent or registration of utility model

Ref document number: 7320741

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360